Clinical Trial Update: A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy [Phase 4]

View source ↗

Summary

Phase 4 trial update on immunological outcomes of sublingual immunotherapy for house dust mite allergy in people with allergic rhinitis and asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma

Drugs mentioned

• House Dust Mite Sublingual Immunotherapy Extract (Dermatophagoides pteronyssinus extract)

Snippet

Sponsor: Bayside Health | Conditions: Allergic Rhinitis, Asthma | Phase 4 | Status: COMPLETED